First Trust Mid Cap Core AlphaDEX

Symbotic Inc. stock price surges by 134%

Guardant Health to showcase liquid biopsy data at San Antonio Breast Cancer Symposium

JP Morgan Analyst Maintains Neutral Rating on Alcoa

Symbotic Inc. prices its 10 million Class A shares at $55 per share to raise $550 million

Madrigal Pharmaceuticals insiders sold $1,380,816 worth of shares

Madrigal Pharmaceuticals CEO Plans to Sell 2,400 Shares of Restricted Stock

Alcoa Exceeds Profit Goals, Discusses Multiple Achievements and Plans

Rosenblatt Raises Lumentum Holding's Target Price to $380

Symbotic Inc. Quarterly Revenue Growth Falls Short of Expectations, Stock Price Gaps Down

Galmed Pharmaceuticals Grants New Use Patent for ARAMCHOL in Combination with Madrigal Pharmaceuticals' REZDIFFRA

Guardant Health insiders sold $5.846 million worth of shares

Guardant Health Exec Monroe Terilyn J Sells $5.8M in Shares

Ciena to release FY2025 Q4 earnings on December 11 Pre-Market EST, forecast revenue USD 1.288 B, EPS USD 0.3266

Madrigal Pharmaceuticals CFO Reports on Stock Disposal

PTC Therapeutics CEO discloses exercising and returning stock

Alcoa Reports 2024 Earnings, Emphasizes Market Leadership

Wells Fargo Analyst Maintains Buy Rating for PTC Therapeutics

Giordano Maintains Symbotic Buy Rating with $75 Price Target

Hecla Mining Company Emphasizes Its Leadership in Silver Mining

Symbotic Executives Sell Class A Common Stock

Treasure Gbl

SMX Security Matters

Gulf Resources

Wheeler Real Estate

Paranovus ENT Tech

Irobot

Dreamland

Praxis Precision Medicines

Alumis

DigitalBridge

Symbotic Inc. (NASDAQ:SYM) shares dropped 17.40% to $60.48 after announcing plans to issue 10 million new shares, affecting investor sentiment.

Symbotic

Symbotic (SYM) nosedives 17% on million-dollar share sale

Symbotic Inc. (NASDAQ:SYM) experienced a significant increase in trading volume, with shares rising 134% from the previous session. Analysts have mixed ratings, with Oppenheimer giving an "outperform" rating and Goldman Sachs downgrading to "sell." The stock's average price target is $56.07. Recent insider sales and institutional investments are noted. Symbotic reported a quarterly revenue increase of 9.5% year-over-year, despite missing earnings estimates.

Market Beat

Symbotic (NASDAQ:SYM) Sees Large Volume Increase  - Should You Buy?

CIEN

Morgan Stanley raised its price target for Ciena (NYSE:CIEN) from $140.00 to $185.00, maintaining an "equal weight" rating. This suggests a potential downside of 5.52% from the current stock price. Other analysts have varied ratings, with a consensus of "Moderate Buy" and a target of $156.20. Ciena's stock performance shows a 52-week high of $214.17 and a market cap of $27.62 billion. Recent insider trading and hedge fund activities are also noted.

Ciena

Ciena (NYSE:CIEN) Price Target Raised to $185.00 at Morgan Stanley

LITE

Lumentum Holdings rose 3.71% in pre-market; SMX Security Matters rose 100.00% in pre-market; Wheeler Real Estate rose 76.82% in pre-market; Dreamland rose 55.88% in pre-market

Tracking Unusual Activity

Lumentum

Pre-market hot trades in US stocks: Rosenblatt raises target price, Lumentum pre-market up 3.71% attracting market attention

Symbotic's shares fell 5% to $57.45 after a $550 million stock offering priced at $55, a 9.1% discount. SoftBank offloaded 3.5 million shares, reducing its stake. The company plans to use proceeds for general purposes. SYM shares had previously surged 39% after Q4 revenue growth. Analysts rate the stock as "hold" with a median price target of $60.50.

Reuters

BUZZ-Symbotic tumbles on $550 mln stock offering as SoftBank slices stake

Shares of U.S.-listed silver miners rose premarket as silver prices increased by 1.9% to $58.19/ounce, driven by strong ETF inflows, rate-cut expectations, and a weaker dollar. Silver has surged 101% this year due to supply deficits and its addition to the U.S. critical minerals list. Hecla Mining rose 1.7%, Coeur Mining 2%, Endeavour Silver 2.5%, and Silvercorp Metals 1.5%. ETFs like Abrdn Physical Silver Shares and iShares Silver Trust also increased by 1.8%.

Silvercorp Met

Endeavour Silver

Coeur Mining

Hecla Mining

BUZZ-Silver miners rise on weaker dollar, rate-cut hopes

J.P. Morgan analyst Bill Peterson maintains a Hold rating for Alcoa with a price target of $45.00. The analyst consensus is a Moderate Buy with an average price target of $40.38. Peterson has an average return of -3.0% and a 44.29% success rate, focusing on the Basic Materials sector.

Tip Ranks

Alcoa

J.P. Morgan Sticks to Its Hold Rating for Alcoa (AA)

Guardant Health will present 14 abstracts at the 2025 San Antonio Breast Cancer Symposium, showcasing advancements in liquid biopsy tests for breast cancer. The presentations will highlight the efficacy of Guardant Reveal and Guardant360 Liquid in detecting cancer recurrence and monitoring treatment response. These studies demonstrate the potential of blood-based testing to guide treatment decisions and improve patient management across various stages of breast cancer.

StockTitan

Guardant Health

Guardant Health to Present 14 Abstracts Demonstrating the Power of Multiomic Liquid Biopsy Tests in Predicting Outcomes and Tailoring Treatment for Early and Metastatic Breast Cancer at the 2025 San Antonio Breast Cancer Symposium | GH Stock News

FNX Inc. has changed its name from S2 Minerals Inc. to FNX Inc. and amended its share structure, re-designating common shares as subordinate voting shares and creating multiple voting shares. The subordinate voting shares now trade under the symbol "FNX" on the Canadian Securities Exchange. No action is required from existing securityholders regarding these changes.

FNX Announces Completion of Name Change and Amendments to Share Structure | SMNRF Stock News

Symbotic Inc :SYMBOTIC ANNOUNCES PRICING OF PRIMARY AND SECONDARY OFFERING OF CLASS A COMMON STOCKSYMBOTIC INC - SHARES PRICED AT $55.00 EACH IN OFFERING

Symbotic Prices Common Stock Offering at $55 Per Share

Guardant Health, Inc.'s common stock is subject to a lock-up agreement ending on December 5, 2025. The lock-up period lasts 31 days, from November 4 to December 5, 2025. During this time, directors and executive officers cannot sell or transfer shares without consent from Goldman Sachs & Co. LLC and Jefferies LLC, with specified exceptions.

marketscreener

Certain Common Stock of Guardant Health, Inc. are subject to a Lock-Up Agreement Ending on 5-DEC-2025.

MDGL

Madrigal Pharmaceuticals Insider Sold Shares Worth $1,380,816, According to a Recent SEC Filing

Madrigal Pharma

Madrigal Pharmaceuticals Insider Sold Shares Worth $1,380,816, According to a Recent SEC Filing

CEO Sibold William John of Madrigal Pharmaceuticals Inc filed a Form 144 with the SEC to sell 2,400 restricted shares on December 4, 2025. The sale will be managed by Morgan Stanley Smith Barney LLC. Form 144 is required for selling restricted stock, allowing the owner to sell within 90 days of filing. The Washington Service offers insider trading analysis and data services.

CEO Sibold Files To Sell 2,400 Of Madrigal Pharmaceuticals Inc [MDGL]

CAPR

SNOW

QURE

LUMN

INTC

ASST

Symbotic(SYM) fell 17.4%, with a trading turnover 592.0 Million USD, and a year-to-date rose 155.1%. Build A Bear(BBW) fell 15.54%, with a trading turnover 76.7 Million USD, and a year-to-date rose 7.1%. Capricor Therap(CAPR) fell 15.22%, with a trading turnover 219.7 Million USD, and a year-to-date rose 84.1%.

- The Nasdaq Composite Index rose by 0.22%, with a year-to-date increase of 21.7%.  
- The S&P 500 Index increased by 0.11%, accumulating a 16.6% rise for the year, while the Dow Jones Index fell by 0.07%, with a 12.5% year-to-date gain.  
- Notable declines included Symbotic (SYM) down 17.4%, Build A Bear (BBW) down 15.54%, and Capricor Therapeutics (CAPR) down 15.22%, despite significant year-to-date gains for each.  